The U.S. Food and Drug Administration (FDA) announced the appointment of 14 members to its Pharmacy Compounding Committee today.
The expert panel members act as advisers on the technical, medical and scientific issues that may come up in the manufacturing of pharmaceutical instruments and medication.
The committee includes 12 voting members and two non-voting members.
“Advisory committees are a very important source of knowledge and advice for drug regulation,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said. “This is a key step toward implementing the compounding provisions of the Drug Quality and Security Act, and I expect we will benefit greatly from the advice and recommendations the members of the committee provide.”
The FDA sends invitations to professional organizations to nominate candidates for the committee. It also nominates candidates from within the federal government. Voting members represent the U.S. Pharmacopeia, a nonprofit organization that sets the standards for the quality, strength, purity and identification of medication; and The National Association of Boards of Pharmacy, an organization that supports state pharmacy boards. One voting member represents consumers and their interests.
The two non-voting members of the committee represent the pharmaceutical manufacturing industry and the compounding industry. Other candidates may not represent a particular group. These individuals are evaluated on the basis of whether they have a conflict of interest by serving on the committee and if they are qualified to advise in the arena.
The members include Drs. Jurgen Venitz, Ned. S. Braunstein, Michael A. Carome, John J. DiGiovanna, Padmar Gulur; and Gigi S. Davidson, Robert DeChristoforo, Stephen W. Hoag, William A. Humphrey, Elizabeth Jungman, William Mixon, Katherine Pham, Allen J. Vaida, and Donna Wall.